Document Detail

Amlodipine and physiological responses to brisk exercise in healthy subjects.
MedLine Citation:
PMID:  10686660     Owner:  NLM     Status:  MEDLINE    
Recent studies have questioned the safety of calcium antagonists in general, and short-acting dihydropyridine derivatives in particular. Reasons include excessive catecholamine stimulation after stress. We therefore wanted to assess whether amlodipine, a second generation dihydropyridine with a prolonged plasma half-life, would show a more favourable haemodynamic and biochemical profile after strenuous exercise. For this purpose, we studied 9 healthy volunteers in a double-blind, randomized, placebo-controlled trial. After 10 days of amlodipine, 5 mg orally daily or placebo therapy, volunteers performed a treadmill effort test; the sequence was repeated after a 2-week washout period. Amlodipine caused a significant increase in mean resting heart rate (HR) (from 65 +/- 3 to 70 +/- 3 beats/min, p < 0.05), without changing systolic or diastolic blood pressure (SBP, DBP). Post-exercise haemodynamic responses were similar while on amlodipine or placebo therapy. Amlodipine did not alter the normal profile of resting or exercise-induced metabolic [plasma glucose, serum K+, serum free fatty acid (FFA)] and hormonal [plasma cortisol, growth hormone, prolactin, insulin, epinephrine (EPI) and norepinephrine (NE)] responses--although plasma EPI concentrations dropped significantly lower (p < 0.05) at 5 min and 15 min post-exercise while on the calcium antagonist. We conclude that amlodipine has a largely neutral effect on the physiological profile after brisk exercise in healthy young subjects and that this may prove to be a useful property for a vasodilator drug.
S Stankovic; V Panz; E Klug; G Di Nicola; B I Joffe
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  13     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1999 Nov 
Date Detail:
Created Date:  2000-03-23     Completed Date:  2000-03-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  513-7     Citation Subset:  IM    
Carbohydrate and Lipid Metabolism Research Group, University of the Witwatersrand, Johannesburg, South Africa.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amlodipine / administration & dosage,  adverse effects,  pharmacology*
Calcium Channel Blockers / pharmacology*
Dihydropyridines / adverse effects,  pharmacology*
Double-Blind Method
Exercise / physiology*
Hemodynamics / drug effects*,  physiology
Hormones / blood,  metabolism*
Time Factors
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Dihydropyridines; 0/Hormones; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of atrial refractoriness and atrial fibrillation inducibility immediately after internal ...
Next Document:  Cilnidipine improves insulin sensitivity in the Otsuka Long-Evans Tokushima fatty rat, a model of sp...